Search results for " Persistence"

showing 10 items of 57 documents

Physical multimorbidity predicts the onset and persistence of anxiety: A prospective analysis of the Irish Longitudinal Study on Ageing.

2022

Background: The aims of the present study were to examine prospective associations of multimorbidity (i.e., >= 2 chronic conditions) at baseline with incident and persistent anxiety over a two-year follow-up period among Irish older adults, and to quantify the extent to which sleep, pain, and disability mediate the multimorbidity-anxiety relationship.& nbsp;Methods: Data from The Irish Longitudinal Study on Aging (TILDA) conducted between 2009 and 2011 with a follow-up after two years were analyzed. Anxiety referred to score >=& nbsp;8 on the anxiety section of the Hospital Anxiety and Depression Scale. Lifetime diagnosis of 14 chronic conditions was obtained. Outcomes were in…

MaleAgingA prospective analysis of the Irish Longitudinal Study on Ageing.- Journal of affective disorders 2022 [Smith L. Shin J. I. Jacob L. Schuch F. Pizzol D. López Sánchez G. F. Soysal P. Tully M. A. Butler L. T. Barnett Y. et al. -Physical multimorbidity predicts the onset and persistence of anxiety]MultimorbidityPainAnxietyPsychiatry and Mental healthClinical PsychologyChronic DiseaseHumansFemaleAnxiety Cohort Epidemiology Multimorbidity Older adultsLongitudinal StudiesAged
researchProduct

Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study

2019

The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption. Purpose: Low persistence with osteoporosis medications is associated with higher fracture risk. This study aimed to assess the persistence to treatment with oral bisphosphonates among Italian osteoporotic patients under treatment for at least 6 months and to evaluate whether the different oral formulations of …

MaleAgingmedicine.medical_specialtyGeneric drugmedicine.medical_treatmentOsteoporosisDrinkable bisphosphonates; Generic drug; Oral bisphosphonates; Osteoporosis; PersistenceAdministration OralPersistence (computer science)Medication AdherencePersistence03 medical and health sciencesFractures Bone0302 clinical medicineInternal medicineGeneric drugmedicineHumansDrinkable bisphosphonatesGeneric drugOral bisphosphonatesOsteoporosisPersistence030212 general & internal medicineMedical prescriptionAdverse effectAgedRetrospective StudiesOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryOral bisphosphonatesSettore MED/34 - Medicina Fisica E RiabilitativaBisphosphonateMiddle Agedmedicine.diseaseDiscontinuationLogistic ModelsItalyCase-Control StudiesOsteoporosisFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryOsteoporotic FracturesDrinkable bisphosphonates
researchProduct

Association of the rs4988235 in the lactase gene with obesity and its modulation by dairy products in a Mediterranean population

2011

The -13910C>T polymorphism (rs4988235) upstream from the lactase (LCT) gene, strongly associated with lactase persistence (LP) in Europeans, is emerging as a new candidate for obesity. We aimed to analyze the association of this polymorphism with obesity-related variables and its modulation by dairy product intake in an elderly population. We studied 940 high-cardiovascular risk Spanish subjects (aged 67 ± 7 years). Dairy product consumption was assessed by a validated questionnaire. Anthropometric variables were directly measured, and metabolic syndrome-related variables were obtained. Prevalence of genotypes was: 38.0% CC (lactase nonpersistent (LNP)), 45.7% CT, and 16.3% TT. The CC genot…

MaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedicine (miscellaneous)LactoseMediterraneanGeneBody Mass IndexEndocrinologyRisk FactorsSurveys and QuestionnairesOdds RatioLactaseMetabolic Syndromeeducation.field_of_studyNutrition and DieteticsMediterranean RegionLactaseMiddle AgedMetabolic syndromeCardiovascular DiseasesFemaleWaist CircumferenceRiskmedicine.medical_specialtyWaistGenotypePopulationArticleAnimal scienceSex FactorsInternal medicinemedicineHumansObesityeducationAllelesAgedPolymorphism Geneticbusiness.industryBody WeightOdds ratiomedicine.diseaseObesityDietLactase persistenceEndocrinologySpainDairy ProductsMetabolic syndromebusinessBody mass indexDairy productsObesity (Silver Spring, Md.)
researchProduct

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct

Marshall's vein persistence: A rare and occasional finding during pacemaker implantation

2012

In adults the oblique vein of Marshall is usually absent or very thin, and it is hard to be found. In this case report we describe a case of persistence observed during pacemaker implantation.

MalePacemaker ArtificialVena Cava SuperiorSettore MED/09 - Medicina InternaHumansPhlebographyMiddle AgedAtrioventricular BlockSettore MED/11 - Malattie Dell'Apparato CardiovascolareMARSHALL’S VEIN PERSISTENCE PACEMAKER IMPLANTATION
researchProduct

Associations of the MCM6-rs3754686 proxy for milk intake in Mediterranean and American populations with cardiovascular biomarkers, disease and mortal…

2016

Controversy persists on the association between dairy products, especially milk, and cardiovascular diseases (CVD). Genetic proxies may improve dairy intake estimations, and clarify diet-disease relationships through Mendelian randomization. We meta-analytically (n T (nonpersistence>persistence), dairy intake, and CVD biomarkers in American (Hispanics, African-American and Whites) and Mediterranean populations. Moreover, we analyzed longitudinal associations with milk, CVD and mortality in PREDIMED), a randomized Mediterranean diet (MedDiet) intervention trial (n = 7185). The MCM6-rs3754686/MCM6-rs309180 (as proxy), LP-allele (T) was strongly associated with higher milk intake, but inconsis…

MalealelosMediterranean dietMETABOLIC RISK-FACTORShumanosSINGLE-NUCLEOTIDE POLYMORPHISMComponente 6 del complejo de mantenimiento de minicromosomasDisease030204 cardiovascular system & hematologyMediterraneanAssociationsDiet MediterraneanMediterranean populationMCM6-rs37546860302 clinical medicineMedicineDisease030212 general & internal medicinemediana edadDAIRY CONSUMPTION2. Zero hungerancianoeducation.field_of_studyBioquímica y tecnologíaMultidisciplinarydietaMediterranean RegionHàbits alimentarisMendelian Randomization AnalysisMiddle AgedLlet3. Good healthBiochemistry and technologyBODY-WEIGHTCardiovascular diseasesMilkAmerican populationCardiovascular DiseasesMeta-analysisMarcadors bioquímicsFOOD-FREQUENCY QUESTIONNAIREFemaleLlet -- Aspectes nutricionalsGenetic MarkersFood habitsPopulationenfermedades cardiovascularesUNITED-STATESSistema cardiovascular malaltiesBioquímica i biotecnologiaArticleDIETleche03 medical and health sciencesSex Factors:Ciencias de la Salud::Medicina preventiva [Materias Investigacion]Sistema cardiovascular -- Malalties -- Aspectes genèticsEnvironmental healthMendelian randomizationMortalitatSNPAnimalsHumansPUERTO-RICANMortalityeducationMilk intakeLACTASE-PERSISTENCE PHENOTYPEAllelescardiovascular biomarkersAgedbusiness.industryMalalties cardiovascularsCardiovascular biomarkersmarcadores genéticosMendelian Randomization AnalysisMinichromosome Maintenance Complex Component 6United StatesDietBiotechnologyCardiovascular diseases (CVD)Lactase persistence2045-2322animalesanálisis de la aleatorización mendelianaDOSE-RESPONSE METAANALYSIS:Ciencias de la Salud::Endocrinología [Materias Investigacion]business
researchProduct

Persistence of Human Bocavirus 1 in Tonsillar Germinal Centers and Antibody-Dependent Enhancement of Infection

2021

Human bocavirus 1 (HBoV1), a common pediatric respiratory pathogen, can persist in airway secretions for months hampering diagnosis. It also persists in tonsils, providing potential reservoirs for airway shedding, with the exact location, host cell types, and virus activity unknown.

NASOPHARYNXviruksetPalatine TonsilFc receptorCHILDRENvirus persistenceMonocytesHuman bocavirusCONGENITAL INSENSITIVITYBokavirusChildviruspersistenssi11832 Microbiology and virology0303 health sciencesB-LymphocytesbiologyHuman bocavirusvasta-aineetDENGUE-VIRUS-INFECTIONrespiratory systemMiddle AgedQR1-5023. Good healthLymphatic systemB-CELLSChild PreschoolAntibodyCELL-LINE U937HUMAN PARVOVIRUSResearch ArticleAdultAdolescentEndosomesMicrobiologyinfektiotVirusHost-Microbe BiologyParvoviridae Infections03 medical and health sciencesYoung AdultImmune systemnielurisaVirologytonsilsHumansAntibody-dependent enhancementRESPIRATORY VIRUSESparvovirukset030304 developmental biologyAgedRECEPTOR030306 microbiologyparvovirusInfant NewbornGerminal centerInfantbiology.organism_classificationGerminal CenterAntibody-Dependent Enhancementrespiratory tract diseasesgerminal centerImmunologyDNA Viralbiology.protein1182 Biochemistry cell and molecular biology3111 Biomedicinein situ hybridizationADEB-soluTRACTmBio
researchProduct

Youth poverty in Europe.

2007

This research examines poverty among young people aged 16 to 29, across 13 countries of the pre-enlargement European Union. Although young adulthood is known to be a time of uncertainty and vulnerability, there has been little research into the incidence of poverty among young people. This report aims to fill this knowledge gap. More life-changing transitions occur during the young adult years than at any other time in people’s lives. This research looks at how these affect young people’s risks of poverty, including events such as: - leaving the parental home - setting up home with a partner - finishing education - finding (or not finding) a job, and - starting a family. The research compar…

POVERTY YOUNG PEOPLE POVERTY PERSISTENCE
researchProduct

Patterns of poverty among elderly Americans: a Latent Class Markov Model

2017

ABSTRACTThis article studies poverty persistence and the role of social security programmes on poverty among elderly in the US. We use a Latent Markov model to disentangle unobserved heterogeneity and state dependence. Because of its dynamic nature, unobserved heterogeneity is modelled to vary over time. This allows to capture different latent states of poverty that change over time. Result indicates the existence of three unobserved types evolving over time according to their propensity to be poor. Moreover, a strong persistence in poverty especially for women, individuals living alone and ethnic minorities is found. Finally, the estimates indicate that giving social assistance tends to re…

Persistence (psychology)Change over timeEconomics and EconometricsClass (computer programming)Poverty05 social sciencesEthnic groupMarkov model01 natural sciences050906 social workSocial securityPoverty persistence older Americans latent Markov model social security programmes010104 statistics & probabilitySettore SECS-P/03 - Scienza Delle FinanzeDevelopment economicsEconomicsState dependenceDemographic economics0509 other social sciences0101 mathematics
researchProduct